Support the EIHA CBD position paper

October 2016, update January 2017

Please support the EIHA activities on CBD by donating

Cannabidiol (CBD) is one of the non-psychotropic cannabinoids in industrial hemp. The last couple of years have seen growing interest in CBD. Cannabidiol not only has a plethora of beneficial health effects, but it also has no relevant side-effects, even when it is administered at high doses. CBD is increasingly used as a food supplement and in food supplement compositions, and ingredient in cosmetics, thereby generating new investments and creating employment in the cultivation and processing of hemp and hemp-derived products. Pharmaceutical products with CBD as an active ingredient have also been developed.

At the moment there is only a tenuous patchwork of CBD-regulations in the EU. The European Industrial Hemp Association (EIHA) supports the development of a harmonized legislation in this field, to make sure that consumers are protected, to sustain the industry’s current double-digit growth rate. The European Industrial Hemp Association (EIHA) is strictly opposed to the attempts by a few pharmaceutical companies to make CBD a prescription-only drug. This only serves the interest of a few companies while damaging the young CBD industry. Such legislation would also restrict the access to CBD for many citizens, who are already profiting from CBD in food and cosmetics. It is EIHA‘s expectation that European and national authorities should not limit the use of CBD in pharmaceuticals (medicinal products) only. There is also no reason to regulate the access to CBD too rigorously, because of the wide spectrum of beneficial physiological effects of CBD and its favourable safety profile.

For different doses and applications of CBD, EIHA proposes a three-tier regulation: At high doses, CBD can be a medicinal product and should be regulated as such. At physiological doses CBD should be regarded as an OTC-product (= over the counter) or a food supplement. This approach is already applied for many substances, such as valerian, glucosamine, chondroitin(sulfate), Ginkgo Biloba, some vitamins and iron products. Low CBD concentrations and doses should be allowed in food products without any restrictions.

The full position paper of the European Industrial Hemp Association (EIHA) on: “Reasonable regulation of cannabidiol (CBD) in food, cosmetics, as herbal natural medicine and as medicinal product” (October 2016, update January 2017) can be downloaded here: 17-01_EIHA-CBD-position-paper.pdf
(the first version is here still available: 16-10_EIHA-CBD-position-paper.pdf)

EIHA asked all patients and citizen profiting from CBD products to sign the position paper.

Read the press release in English, German or Czech.


Sign the position paper now

I would like to support the EIHA CBD position paper and appear in the list of supporters.
 


List of supporters

Page 14 of 16« First...1213141516